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ABSTRACT
Aminoacyl-tRNA synthetases (ARS) are a family of enzymes that catalyze the
charging of amino acids to their cognate tRNA in an aminoacylation reaction. Many
members of this family have been found to have secondary functions independent of their
primary aminoacylation function. Threonyl-tRNA synthetase (TARS), the ARS
responsible for charging tRNA with threonine, is secreted from endothelial cells in
response to both vascular endothelial growth factor (VEGF) and tumor necrosis factor-α
(TNF-α), and stimulates angiogenesis and cell migration. Here we show a novel
experimental approach for studying TARS secretion, and for observing the role of
intracellular TARS in the endoplasmic reticulum (ER) stress response and in
angiogenesis.
Using Western blotting, immunofluorescence microscopy and RT-qPCR we were
able to investigate changes in TARS protein and transcript levels. We initially
hypothesized that TARS was secreted by exosomal release, and so we treated a human
ovarian cancer cell line (CaOV-3) with monensin, an ionophore that increases exosome
production, and VEGF to observe changes in intracellular and extracellular TARS
protein. Monensin treatment consistently increased extracellular and intracellular TARS
protein, however CD63, an exosome marker protein, levels were unaffected by monensin
treatment. VEGF had no effect on intracellular TARS. We therefore hypothesized that the
TARS response was a result of ER stress.
The unfolded protein response (UPR) is a series of signaling pathways that are
activated upon ER stress. When CaOV-3 cells were treated with increasing
concentrations of monensin, intracellular levels of TARS and p-eIF2α, a downstream
UPR target, increased accordingly. Monensin increased intracellular TARS protein and
transcript levels in CaOV-3 cells. Monensin also increased DNAJB9, an ER chaperone
protein, transcript levels, further confirming ER stress. Interestingly, monensin increased
VEGF transcript levels about 6-fold. Borrelidin, a natural TARS inhibitor, also increased
VEGF transcript levels, and caused an increase in p-eIF2α protein.
Although the mechanism of TARS secretion remains unresolved, these data
indicate that intracellular TARS expression increases in response to ER stress by
monensin. Given TARS and VEGF transcript expression increased accordingly, it is
possible that intracellular TARS may have pro-angiogenic function. Future directions
may include investigating TARS interactions with translational control machinery.
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CHAPTER 1: INTRODUCTION

1.1 Aminoacyl-tRNA Synthetase Primary Function

1.1.1 Aminoacyl-tRNA Synthetases are Vital for Translation
Aminoacyl-tRNA synthetases (ARSs) are responsible for charging transfer
ribonucleic acid (tRNA) molecules with their cognate amino acids via an aminoacylation
reaction. ARSs were first discovered by their ability to activate amino acids and transfer
those amino acids to tRNA in the presence of microsomal RNA fractions from rat liver
and adenosine triphosphate (ATP) (Zamecnik and Keller 1954, Hoagland, Stephenson et
al. 1958). ARSs are evolutionarily conserved across kingdoms, as this reaction is
necessary for global translation (Szymanski, Deniziak et al. 2001). In order to ensure
amino acid fidelity when charging tRNA molecules each tRNA species has a subsequent
ARS, with some exceptions (Ibba, Becker et al. 2000). The following highlights the twostep reaction ARSs catalyze:
a) AA + ATP ! AA-AMP + PPi
b) AA-AMP + tRNAAA ! AA-tRNAAA +AMP
In part (a) of this reaction, the synthetase reacts its cognate amino acid (AA) with
a molecule of ATP to produce an adenylate intermediate (AA-AMP) and inorganic
phosphate (PPi). AA-AMP remains bound in the active site of the enzyme. The
corresponding tRNA (tRNAAA) then enters the active site, and the amino acid’s carboxyl
group binds to either the 2’ or 3’-OH of the 3’end of the tRNA thus transferring from the
ARS to the tRNA. The charged tRNA is then released from the ARS and can be recruited
1

for translation. This model suggests that these are two separate reactions where in reality
there is coupling between the two reactions, which is vital for proper ARS function. This
reaction comprises the primary function of all ARSs.
ARSs can be categorized into two different classes. Class I synthetases have a
Rossmann fold, a parallel β-sheet, located in their active site, and bind tRNA in the minor
groove of the acceptor stem where they aminoacylate on the tRNA 2’-OH (Ibba, Becker
et al. 2000). Class I synthetases also share the sequence motifs HIGH and KMSKS, and
are typically monomeric when active (Arnez and Moras 1997). In contrast, class II
synthetases have an antiparallel β-sheet in their active site, which is surrounded by αhelices, and bind tRNA in the major groove of the acceptor stem where the 3’-OH is
aminoacylated (Arnez and Moras 1997, Ibba, Becker et al. 2000). This class of
synthetases typically exists as a dimer or multimer upon catalytic activation. Class II
synthetases share sequence motifs, referred to as motifs 1, 2 and 3, which are structurally
vital for enzyme function. Motif 1 consists of an α-helix linked to a β-strand, and is
located at the dimer interface of class II ARSs, while motifs 2 and 3 are found in the
active site of the enzyme, and consist of two anti-parallel β-strands linked by a loop and a
β-strand followed immediately by an α-helix, respectively (Arnez and Moras 1997). Two
exceptions to these parameters are lysyl-tRNA synthetase (KARS), which is both a class I
and class II synthetase, and phenylalanyl-tRNA synthetase (FARS), which is a class II
synthetase that aminoacylates on the 2’-OH of tRNA (Ibba, Becker et al. 2000).

2

1.1.2 Maintaining Fidelity When Charging tRNA Molecules
ARSs are vital for proper protein synthesis, and so they must have a high rate of
fidelity for aminoacylating tRNA molecules with their cognate amino acids. ARSs must
distinguish correct tRNA and amino acid molecules to ensure the correct tRNA
molecules are charged with their cognate amino acids. This process aims to combat
mutations during translation. Cognate tRNA molecules are distinguished by interactions
with specific nucleotides on the tRNA, known as identity elements (Giege, Sissler et al.
1998). This recognition has shown little error. It is reported that 1 in 107 misidentification
events occur, which would not contribute greatly to overall translational error
(Jakubowski and Goldman 1992). Incorporation of cognate amino acids into AA-tRNAAA
complexes requires a more complicated editing mechanism.
ARSs need to be able to distinguish between cognate and non-cognate amino
acids with high fidelity in order to mitigate mutational errors in translation. Some amino
acids are structurally similar, and cannot be easily distinguished by ARSs. For example,
valine and isoleucine differ in structure by a single methyl group. The fidelity of
synthetases is maintained by a two-step editing process know as the “double sieve
model” (Sankaranarayanan and Moras 2001).
This enzyme hyperspecificity was first rationalized in 1976 by Fersht and
Kaethner who showed a low rate of misincorporation of threonine onto tRNAVal by valyltRNA synthetase (VARS) (Fersht and Kaethner 1976). They proposed a two-step model.
First, cognate and near-cognate amino acids are filtered out from larger amino acids in
the active site, and charged accordingly in an adenylation reaction. Second, mischarged
amino acids are hydrolyzed to ensure misincorporation during translation does not occur.
3

For example, VARS will charge threonine and form a complex with a threonyl-adenylate
at 1:1, however when a Thr-VARS-tRNAVal complex forms, the aminoacylated product is
rapidly hydrolyzed (Fersht and Kaethner 1976). The term double sieve model was coined
for this process shortly thereafter (Fersht and Dingwall 1979).
Since then, the double sieve model has been further examined, and the original
hypothesis by Fersht and Kaethner has been modified by crystal structure analysis and by
monitoring acylation activity (Martinis and Boniecki 2010). The first step in editing
consists of the “coarse sieve”, which refers to amino acids of similar size, cognate and
non-cognate, binding in the active site of the ARS, while larger amino acids are typically
excluded due to steric hindrance (Sankaranarayanan and Moras 2001). In the case of
isoleucyl-tRNA synthetase (IARS), valine and isoleucine differ by only one methyl
group, which translates to a difference of about 1 kcal/mol of binding energy difference
(Nureki, Vassylyev et al. 1998). IARS therefore misincorporates valine for isoleucine at a
rate of about one in five thus creating a thermodynamically unfavorable model for onestep discrimination (Nureki, Vassylyev et al. 1998). A second editing step has evolved to
counter this high rate of misincorporation.
“Fine sieve” editing refers to hydrolysis of false cognates, and can be further
categorized into pre-transfer and post-transfer editing. The pre-transfer mechanism
involves hydrolysis of the false cognate adenylate intermediate, while the post-transfer
mechanism involves deacylation of the incorrectly charged tRNA (Sankaranarayanan and
Moras 2001). IARS primarily employs pre-transfer editing. Valyl-adenylate intermediates
are hydrolyzed in the presence of tRNAIle while isoleucyl intermediates are successfully
transferred to tRNAIle as demonstrated in E. coli and T. thermophilus (Baldwin and Berg
4

1966, Nureki, Vassylyev et al. 1998). Post-transfer editing occurs in a second hydrolytic
site separate from the active site (Martinis and Boniecki 2010). ARSs that employ this
mechanism will charge tRNA with non-cognate adenylate intermediates, and then
transfer the complex to the hydrolytic site. tRNA molecules charged with cognate amino
acids do no fit in this site and are released. Pre- and post-transfer mechanisms are
sometimes both present in the same ARS, suggesting redundancy in editing (Martinis and
Boniecki 2010).
Class I synthetases have a conserved CP1 domain in their active site, which is
employed for editing non-cognate substrates (Marintchev 2012). In contrast class II
synthetases vary in their structural organization resulting in specific motifs that create
variance in editing mechanisms across ARSs (Marintchev 2012). One of the most well
understood mechanisms of class II synthetase editing is that of threonyl-tRNA synthetase
(TARS).
TARS has a molecular weight of 83 kiloDaltons and dimerizes to gain catalytic
activity. During editing, TARS has to distinguish between threonine, serine and valine
when charging tRNAThr molecules. Valine is isoteric with threonine, the cognate
substrate, and serine differs from threonine by one methyl group. TARS has a zinc ion in
its active site, which is coordinated by three residues and a water molecule (Marintchev
2012). This zinc ion acts as a cofactor in amino acid recognition, interacting with the
hydroxyl side chains of threonine and serine (Sankaranarayanan and Moras 2001).
Therefore, valine is entirely excluded by TARS due to its lack of a hydroxyl group
(Marintchev 2012). TARS then uses its N-terminal N2 domain to employ a post-transfer
editing mechanism to hydrolyze Ser-tRNAThr complexes (Dock-Bregeon,
5

Sankaranarayanan et al. 2000, Sankaranarayanan and Moras 2001, Marintchev 2012).
TARS utilizes a chemical “coarse sieve” following by a more traditional post-transfer
“fine sieve” when discriminating between cognate and non-cognate amino acids.

1.2 Aminoacyl-tRNA Synthetases in Disease

1.2.1 Introduction to Synthetases in Disease
Proper ARS function, including fidelity in aminoacylation, is not only important
for maintaining translation integrity, but also for preventing disease. Mutations in ARSs
play a role in pathology, as these mutations often inhibit tRNA aminoacylation and
disrupt protein synthesis (Yao and Fox 2013, Abbott, Francklyn et al. 2014). Synthetase
dysfunction has been linked with neurodegenerative disorders, angiogenesis,
tumorigenesis and inflammation (Yao and Fox 2013, Abbott, Francklyn et al. 2014). It
has been reported in mice that a missense mutation in the editing domain of alanyl-tRNA
synthetase (AARS) causes cerebellar Purkinje cell loss and ataxia showing direct
correlation with loss of editing function and disease (Lee, Beebe et al. 2006). In contrast,
Charcot-Marie-Tooth disease (CMT) has been linked with mutations in KARS, glycyltRNA synthetase (GARS), AARS, tyrosyl-tRNA synthetase (YARS) and histidyl-tRNA
synthetase (HARS) that do not lead to loss of editing function (Yao and Fox 2013,
Abbott, Francklyn et al. 2014). ARSs’ roles in various diseases have yielded insight into
secondary functions of this family of enzymes.
Synthetases and their associated factors are well established in the roles they play
in diseases. Specifically, these molecules contribute to neurodegenerative disorders,
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autoimmune disorders and cancer progression. This has rendered many members of the
ARS family valid targets for pharmacological intervention.

1.2.2 Neurodegeneration
The majority of the 20 standard amino acids have two synthetases associated with
them, a cytoplasmic and mitochondrial species (Kurland and Andersson 2000).
Mitochondrial synthetases play a role in synthesis of components of the mitochondrial
oxidative phosphorylation system, while cytoplasmic synthetases are involved in more
global protein synthesis (Konovalova and Tyynismaa 2013). As a result, there are
diseases associated with synthetases of both mitochondrial and cytoplasmic ARSs.
Mitochondrial tRNA and mitochondrial ARS mutations contribute to many
neurodegenerative diseases. Briefly, the mitochondrial genome encodes for all RNA
necessary for translation in the mitochondria, however proteins necessary for protein
synthesis in the mitochondria, such as ARSs, ribosomal proteins etc., are encoded for in
the nucleus, and are synthesized in the cytoplasm and transported into the mitochondria
(Abbott, Francklyn et al. 2014). Mitochondrial tRNA mutations accumulate over the
course of an organism’s life cycle, and ultimately manifest in disease (Abbott, Francklyn
et al. 2014). Two well characterized diseases resulting from this accumulation are
mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS)
and myoclonic epilepsy with ragged red fibers (MERRF) (Abbott, Francklyn et al. 2014).
These diseases can lead to symptoms including epilepsy, seizures and limb weakness.
80% of MELAS patients contain an A3243G mutation in the tRNALeu gene, while 8090% of MERFF patients exhibit an A8344G mutation in the tRNALys gene (Silvestri,
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Moraes et al. 1992, Suzuki, Nagao et al. 2011). MELAS mutations lead to impaired
oxidative phosphorylation due to defects in respiratory chain complexes I and IV
(Abbott, Francklyn et al. 2014). In addition, in both MELAS and MERFF patients a
G12147A mutation was found in tRNAHis, which was linked with a decrease in
cytochrome c oxidase by succinate dehydrogenase staining and a decrease in
mitochondrial protein synthesis (Melone, Tessa et al. 2004). These diseases highlight
how mitochondrial tRNA mutations lead to dysfunctional mitochondria and subsequent
modulation of brain function.
Mutated mitochondrial ARSs have also been linked with diseases of the brain.
Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation
(LBSL) is an autosomal recessive disorder that manifests in and contributes to changes in
the white matter, which can lead to cerebellar ataxia, spasticity and dorsal column
dysfunction (van Berge, Dooves et al. 2012, Konovalova and Tyynismaa 2013). LBSL is
caused by mutations in the mitochondrial aspartyl-tRNA synthetase (DARS) gene with
the most common mutation found in intron 2 across patients, which is important in the
proper splicing of exon 3 (van Berge, Dooves et al. 2012). It was found that this mutation
has the largest effect on exon 3 exclusion in patient neural cells compared with nonneural cells, and these neural cells also have more difficulty with correct inclusion of
exon 3 than non-neural cells (van Berge, Dooves et al. 2012). This study not only links a
mutated ARS with neurodegeneration, but also shows that these mutations are tissue
specific. Tissue specificity is common in mitochondrial ARS and tRNA mutation
phenotypes.
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A common cytoplasmic ARS-associated disease is Charcot-Marie-Tooth
syndrome (CMT). CMT is a neurodegenerative disease that is a result of peripheral
neuropathy or degeneration of distal motor and sensory neurons. It ultimately leads to
muscle weakness, altered gait and balance and general decline of leg and arm function.
Six ARS mutations have been linked to CMT including AARS, GARS, HARS, KARS,
methionyl-tRNA synthetase (MARS) and YARS (Yao and Fox 2013, Abbott, Francklyn
et al. 2014). G41R, E196K and Δ153-156 deletion mutations in YARS are linked with
CMT (Jordanova, Irobi et al. 2006). Specifically, these mutations are associated with
deteriorated canonical function of YARS, but this loss of function is not linked with
CMT contribution (Jordanova, Irobi et al. 2006). YARS localizes to neuronal cells, and
transfection with either wild type (WT) or mutant YARS into N2a cells shows no
difference in localization patterns (Jordanova, Irobi et al. 2006). Therefore mutant YARS
can be expected to affect neuronal cells. This is an example of how investigating
synthetase mutants further may yield insight into neurodegeneration.

1.2.3 Synthetases are Involved in Autoimmunity
The ARS family is also associated with the autoimmune response. Autoimmunity
refers to in vivo synthesis of antibodies against epitopes of non-foreign proteins, typically
leading to protein dysfunction and subsequent disruption of cell health. Therefore,
synthetases provide autoantigens that the body creates autoantibodies against, which
intermittently sustains the autoimmune response. Myositis is an autoimmune disorder
resulting in inflammation and weakness of muscle tissue. HARS and TARS both contain
autoantigens associated with myositis (Miller, Waite et al. 1990, Williams, Mirando et al.
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2013, Zhou, Wang et al. 2014). With respect to HARS, it has been well established that
in myositis patients there are autoantibodies against HARS that are dependent on 3D
enzyme structure and on tRNAHis binding in the active site of HARS (Miller, Waite et al.
1990, Zhou, Wang et al. 2014). HARS autoantibodies also undergo maturation to their
target autoantigen, which solidifies the autoimmune response (Miller, Waite et al. 1990).
TARS is the target of the autoantibody PL-7, and its targeting elicits a strong cytokine
response, which has been associated with interstitial lung disease (Labirua and Lundberg
2010). The involvement of ARSs with autoimmune disorders furthers their validity for
pharmacological targeting.

1.2.4 Synthetase Effects on Tumor Progression
When a cell becomes cancerous, various molecular and physiological events must
occur in order to promote the proliferation and spread of the mutated cell. The
accumulated mutations must be maintained throughout cell division, and the cancer cell
must promote proper nutrient and growth factor recruitment in order to survive and
spread. There is recent evidence supporting many members of the cytoplasmic ARS
family being involved in progression of various tumors (Kim, You et al. 2011).
ARS involvement in tumor development has been widely categorized.
Catalytically active MARS has been found to be elevated in colon cancer tissue
(Kushner, Boll et al. 1976). This suggests that the tumor microenvironment may be trying
to increase its total protein synthesis. Of note, MARS transcript was found to share a 55
base pair sequence homology with C/EBP homologous protein (CHOP) transcript,
overlapping in their 3’ UTR regions, which allows the two mRNAs to interact in vivo
10

(Ubeda, Schmitt-Ney et al. 1999). CHOP is typically a regulator of the unfolded protein
response, however it has been found to be amplified in various cancers (Forus, Florenes
et al. 1994). The interaction between the two transcripts promotes stability, and although
this link has not been clearly linked with tumor progression, there is evidence supporting
the possibility (Ubeda, Schmitt-Ney et al. 1999). In addition to its transcriptional
interaction with CHOP, MARS is also a part of the multi synthetase complex (MSC),
which serves as an integrating point for non-canonical ARS activity involved in
tumorigenesis (Kim, You et al. 2011).
The MSC consists of D-, glutamyl-prolyl (EP)-, I-, K-, leucyl (L)-, M-, glutaminyl
(Q)- and arginyl (R)-tRNA synthetases, and it interacts with three auxiliary cofactors,
ARS-interacting multifunctional protein-1 (AIMP-1), AIMP-2 and AIMP-3 (Ray, Arif et
al. 2007). AIMP-1, AIMP-2 and AIMP-3 interact with RARS, KARS and MARS,
respectively. These multifunctional proteins are intricately interwoven with tumor
regulatory pathways. Upon DNA mutation, AIMP-2 is phosphorylated leading to its
dissociation from the MSC (Han, Park et al. 2008). AIMP-2 then binds and activates p53
protein, which inhibits binding of mouse double minute 2 homolog (MDM2) and
subsequent ubiquitinylation and degradation of p53 (Han, Park et al. 2008). AIMP-2 has
also been found to increase HEK293 cell’s sensitivity to tumor necrosis factor-α (TNF-α)
induced apoptosis by targeting TNF receptor associated factor 2 (TRAF2) for
ubiquitinylation and degradation (Choi, Kim et al. 2009). This exemplifies the close
interaction the MSC has with tumor regulatory pathways, and raises question as to what
may occur if the complex were misregulated or mutated.
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ARS protein expression in cancer cells themselves yields insight into possible
roles different synthetases play in cancer. In SKOV-3 cells, an ovarian cancer cell line,
TARS is secreted in response to TNF-α, similarly to endothelial cells (Williams, Mirando
et al. 2013, Wellman, Eckenstein et al. 2014). TARS is overexpressed in ovarian
carcinoma cells, and TARS concentration in these cells increases as tumor stage increases
(Wellman, Eckenstein et al. 2014). Finally, TARS was found to coexpress with VEGF by
immunohistochemistry in infiltrating leukocytes in ovarian cancer tumors (Wellman,
Eckenstein et al. 2014). Taken together, these data propose ovarian cancer cells as a valid
in vitro model for studying TARS expression as it relates to cancer.
In contrast, tryptophanyl-tRNA synthetase (WARS) has low expression levels in
colorectal cancer (Ghanipour, Jirstrom et al. 2009). Low WARS expression was
correlated with an increased risk of lymph node metastasis, and a lower survival rate than
patients with increased WARS expression in cancer cells (Ghanipour, Jirstrom et al.
2009). WARS is anti-angiogenic, and so its decreased expression in colorectal cancer
cells is likely acting as a protective mechanism to enable the tumor cell to increase its
ability to promote angiogenesis (Tzima and Schimmel 2006). The difference in
expression levels of different ARSs in cancer cells shows that the role of synthetases
expands beyond increasing protein translation in tumor cells.
ARSs have also been shown to incorporate molecular events into direct
physiological responses related to cancer. Several ARS family members are involved in
promoting the formation of new microvasculature through angiogenesis, which could
enhance the tumor growth capacity and facilitate metastasis.
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1.3 Angiogenesis

1.3.1 Angiogenesis Background
Angiogenesis is the growth of new blood vessels from pre-existing vasculature,
and is carried out in healthy and diseased tissue (Adair and Montani 2010). Because of its
involvement in cancer, heart disease and other common diseases, angiogenesis has gained
attention over the past few decades. Although the core mechanism of angiogenesis is well
understood, there are other molecular players in different tissues and diseases that are
involved in angiogenesis whose mechanisms of action remain unknown.
In a growing vertebrate embryo, mesodermal cells will ultimately differentiate
into hematopoietic stem cells and angioblasts, which further differentiate into
hematopoietic cells and endothelial cells respectively (Adair and Montani 2010).
Endothelial cells arrange to form hollow tube structures that classify the vasculature.
Therefore angioblast differentiation must be tightly regulated to ensure proper
vasculogenesis in the developing embryo. Angiogenesis links two existing blood vessels
together in poorly perfused tissue when the microenvironment becomes hypoxic (Adair
and Montani 2010). When vascular endothelial cells are exposed to a high concentration
of vascular endothelial growth factor (VEGF) under hypoxia they become tip-cells,
which facilitate endothelial cell migration (Adair and Montani 2010). These tip-cells
guide the new vasculature through the extracellular matrix, and ultimately lead to fusion
with another blood vessel (Adair and Montani 2010). As aforementioned, this process is
vital for tumor cell metastasis. VEGF also influences several ARSs’ angiogenic activity.
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VEGF is a pro-angiogenic autocrine signaling molecule in many cancers that aims
to promote angiogenesis (Duffy, Bouchier-Hayes et al.). It is believed that VEGF
translation may protect tumor cells from apoptosis as a result of this signaling. In breast
carcinoma cells α6β4 integrin signaling was found to upregulate VEGF translation,
which led to an overall increase in cell survival (Chung, Bachelder et al. 2002).
Specifically, α6β4 integrin activates phosphoinositide-3 kinase (PI3-K) and protein
kinase-B (Akt) pathways which stimulate the nutrient sensing mTOR. This causes the
phosphorylation of 4E-binding protein (4E-BP), which allows eukaryotic initiation
factor-4E (eIF4E) to dissociate from 4E-BP and stimulate VEGF translation specifically
(Fig. 1) (Chung, Bachelder et al. 2002). The increase in VEGF expression protects breast
carcinoma cells from apoptosis, and increases their chances of proliferation and
angiogenesis.

Figure 1: Mechanism of increased VEGF translation by α6β4 integrin activation.
Adapted from (Duffy, Bouchier-Hayes et al.).
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1.3.2 Synthetase Angiogenic Activity
Several ARSs have been found to affect angiogenesis both intracellularly and
extracellularly. YARS, WARS and TARS are secreted out of the cell, and stimulate
signaling events extracellularly that affect angiogenesis while seryl-tRNA synthetase
(SARS) and EPRS act intracellularly to change levels of VEGF transcription and
translation, which alters the angiogenic state of the cell (Mirando, Francklyn et al. 2014).
YARS is cleaved by polymorphonuclear leukocyte (PMN) elastase upon secretion from
endothelial cells yielding N- and C-terminal fragments (Mirando, Francklyn et al. 2014).
The N-terminus, or “mini-YARS”, is found to have catalytic activity and to stimulate
angiogenesis through extracellular signal-regulated kinase (ERK) 1, ERK 2, Akt, Src and
endothelial nitric oxide synthase (eNOS) signaling pathways (Mirando, Francklyn et al.
2014). These signaling pathways are pro-angiogenic, indicating likely involvement of
VEGFR2 and integrin receptors (Munoz-Chapuli, Quesada et al. 2004). The C-terminus
YARS fragment’s role is less characterized. WARS either undergoes a cleavage by PMN
elastase once secreted from endothelial cells thus removing its WHEP domain, or WARS
transcript can be alternatively spliced and translated yielding partial WARS that is then
secreted from the cell (Mirando, Francklyn et al. 2014). The “mini-WARS” fragment
then has an inhibitory effect on angiogenesis, which is a result of inhibition of
phosphorylation of ERK, Akt and eNOS downstream targets and prevention of VEGFmediated angiogenesis (Tzima, Reader et al. 2003). The secretion mechanism of both
WARS and YARS remains unresolved.
SARS and EPRS alter VEGF expression intracellularly to inhibit angiogenesis. In
endothelial cells SARS is transported to the nucleus by a nuclear localization signal, and
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inhibits c-Myc-mediated vegfa transcription by altering the epigenetics of the vegfa gene
(Mirando, Francklyn et al. 2014). This produces an angiostatic effect. The bi-functional
EPRS is bound in the MSC under normal conditions. Upon treatment of endothelial cells
with interferon-λ (IFN), EPRS is phosphorylated and dissociates from the MSC
(Sampath, Mazumder et al. 2004). EPRS has been found to been a part of the IFN-λactivated inhibitor of translation (GAIT) complex for binding ceruloplasmin mRNA
(Sampath, Mazumder et al. 2004). Upon phosphorylation, EPRS will associate with this
complex, and bind the 3’ UTR of ceruloplasmin mRNA directly, which inhibits
translation of the transcript (Sampath, Mazumder et al. 2004). This result was extended
when it was found that the GAIT complex also binds the 3’ UTR of VEGFA transcript
thereby inhibiting VEGFA synthesis (Ray and Fox 2007). The WHEP domain of EPRS is
responsible for this interaction. This shows that EPRS plays a role in inhibition of
angiogenesis upon cytokine stimulation.
TARS exhibits extracellular, pro-angiogenic effects in endothelial cells. This
property has predominantly been shown using the TARS inhibitor, borrelidin. Borrelidin
is a compound produced in S. rocheii, which acts as an antibacterial, antiviral and
antifungal agent. It is an 18-membered macrolide ring, and is a potent inhibitor of TARS
as well as an inhibitor of angiogenesis and metastasis in various rat models (Mirando,
Fang et al. 2015). Due to its strong inhibition of TARS, borrelidin is highly cytotoxic to
cells, which is a result of the amino acid starvation response (Mirando, Fang et al. 2015).
BC194 is a borrelidin analog that is less toxic to cells, but inhibits TARS just as strongly
as borrelidin due to maintenance of key substrate binding residues in the active site
(Mirando, Fang et al. 2015). Endothelial cells show decreased tube formation in tube
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assays, a model for angiogenesis, and decreased cell migration upon treatment with
BC914 (Williams, Mirando et al. 2013, Mirando, Fang et al. 2015). The anti-angiogenic
property of BC194 has been confirmed in vivo using zebrafish as a model organism
(Mirando, Fang et al. 2015). In addition, chorioallantoic membrane (CAM) assay on
chicken embryos reveal that when TARS is added exogenously to embryos the
vasculature expands, and when TARS is added exogenously to endothelial cells tube
formation increases (Williams, Mirando et al. 2013). These findings confirm that TARS
is pro-angiogenic. Similar to WARS and YARS, the secretion mechanism remains
unknown for TARS. However, upon treatment with VEGF or TNF-α, endothelial cells
have an increase in TARS in the cell culture media (Williams, Mirando et al. 2013). This
further suggests that TARS is secreted for the purpose of promoting angiogenesis.

1.3.3 Possible Mechanism of Synthetase Secretion
One possible mechanism that synthetases are getting secreted out of cells is by
exosomal release. Exosomes are small vesicular particles between 40-100 nm in diameter
that are vital for cell signaling as they have been found to contain specific RNA and
protein cargo. There is no definite consensus on how exosomes are secreted out of cells,
however the predominant theory will be discussed here. Early endosomes pinch towards
the cytosol from the plasma membrane of the secreting cell (Bobrie, Colombo et al.
2011). Early endosome maturation to a multivesicular body (MVB) is characterized by
further pinching of the membrane away from the cytosol, and towards the extracellular
space. These smaller vesicles in the MVB are often exosomes. The MVB then fuses with
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the plasma membrane releasing its contents, and the exosomes are secreted from the cell
(Fig. 2) (Bobrie, Colombo et al. 2011).
Various families of proteins known to facilitate vesicular trafficking and docking
are thought to enable this process. Exosomes can be tracked experimentally by looking at
proteins bound in exosomal membranes, including CD63 and MHC class II proteins
(Bobrie, Colombo et al. 2011). In this study, we observed changes in CD63 protein levels
to draw conclusions about exosome production in ovarian cancer cells.

Fig. 2: Proposed mechanism of exosome formation and subsequent release. Used
with permission from (Bobrie, Colombo et al. 2011).
It has been observed that cytoplasmic synthetase mRNA from several family
members is found in exosomes in Jurkat cells (Wang, Xu et al. 2013). This raises the
question of what role these mRNA will ultimately play translationally, and begins to
outline possible mechanisms for ARS secretion. In addition, many members of the ARS
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family have been identified in exosomes of cancer cells. A large scale proteomic analysis
found that several cytoplasmic and mitochondrial synthetase proteins can be found in
both OVCAR-3- and IGROV1-, two ovarian cancer cell lines, derived exosomes,
including TARS (Liang, Peng et al. 2013). With knowledge that extracellular TARS is
pro-angiogenic in endothelial cells and that TARS is found in ovarian cancer cell-derived
exosomes, we aimed to test whether TARS was secreted from ovarian cancer cells via
exosomal release in order to further the mechanism by which TARS promotes
angiogenesis.

1.4 Endoplasmic Reticulum Stress Response

1.4.1 Endoplasmic Reticulum Stress and the Unfolded Protein Response
When cells are diseased they experience some level of stress, which is
characterized by stimulation of the immune response, changes in intracellular molecular
status or an alternate response. One specific type of stress response is endoplasmic
reticulum (ER) stress. The ER is responsible for facilitating proper protein folding, and
when unfolded protein accumulates the unfolded protein response (UPR) will be elicited.
The UPR is a complex web of molecular cascades that trigger either a survival response
or an apoptotic response following ER stress.
Three receptors are bound in the ER membrane that regulate the UPR, inositolrequiring protein-1α (IRE1α), PRKR –like ER kinase (PERK) and activating
transcription factor 6 (ATF6) (Oslowski and Urano 2011). IRE1α and PERK have similar
ER-luminal domains and cytosolic kinase domains while ATF6 has a cytosolic cAMP
19

response element binding protein (CREB)-ATF basic leucine zipper domain (Wang and
Kaufman 2016). All receptors constitutively bind immunoglobulin protein (BiP) on the
ER-luminal side. Upon misfolded protein accumulation, BiP binds the misfolded protein
and leaves the receptors nude. Nude receptors are believed to activate the UPR (Wang
and Kaufman 2016). Activation of these three signaling cascades initially triggers three
transcription factors that promote transcription of genes involved in protein folding and
quality control, ER biogenesis, autophagy and other processes that aid in proper protein
folding (Hetz 2012). IRE1α dimerizes and autophosphorylates upon activation, and
facilitates splicing of X-box-binding protein-1 (XBP1) mRNA, which allows XBP1s to
act as a transcription factor for genes promoting cell survival (Wang and Kaufman 2016).
PERK and ATF6 pathways have also been shown to play a role in induction of XBP1 and
its splicing, highlighting interplay often found in the UPR (Yoshida, Matsui et al. 2001,
Tsuru, Imai et al. 2016). PERK dimerizes and autophosphorylates upon activation, which
leads to phosphorylation of Ser51 on eukaryotic initiation factor-2α (eIF2α) thereby
inhibiting global protein translation (Wang and Kaufman 2016). Phosphorylation of
eIF2α also induces translation of ATF4, which acts as a transcription factor for survivalpromoting genes (Hetz 2012). ATF6 activation leads to ATF6α transit to the Golgi
apparatus where it is cleaved by the enzymes S1P and S2P, and this cleavage product acts
as a transcription factor at target genes (Wang and Kaufman 2016). These pathways
promote proper protein folding and cell survival, which classifies the adaptive response
(Fig. 3).

20

Fig. 3: Diagram of UPR signaling pathways. Used with permission from (Walter and
Ron 2011).
The maladaptive UPR occurs as time of the ER stress increases, which
subsequently increases the intensity of the stress. The maladaptive response results in
apoptosis. Following prolonged exposure to tunicamycin or thapsigargin, two known ER
stressors, fibroblasts exhibit decreased XBP1 mRNA splicing, increased full-length
ATF6 coupled with decreased active ATF6, and increased p-eIF2α and ATF4 (Lin, Li et
al. 2007). Levels of CHOP, a pro-apoptotic protein downstream of PERK, are also
increased, suggesting an alternative function for ATF4 (Lin, Li et al. 2007). Additionally,
in an ER stress model in Drosophila, PERK was found to independently trigger apoptosis
(Demay, Perochon et al. 2014). Taken together, these data indicate that under prolonged
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ER stress IRE1α and ATF6 pathways are diminished and sustained PERK activity leads
to apoptosis. This outcome is likely a result of inability of the cell to facilitate proper
protein folding, and so to avoid mutation or dysfunction it undergoes apoptosis.

1.4.2 General Control Nonderepressible 2
The ARS family’s vital role in translation renders these enzymes likely players in
the UPR. ARSs can act as nutrient detectors due to their interactions with amino acids.
When specific amino acids are absent, ARSs will not be able to carry out aminoacylation
reactions leading to loss of function. This amino acid deprivation response can be
detected by the protein complex general control nonderepressible 2 (GCN2). Similar to
PERK, GCN2 is activated by amino acid deprivation, and catalyzes phosphorylation of
eIF2α (Hamanaka, Bennett et al. 2005). This regulation occurs independent of ER stress
and PERK induction, however both PERK and GCN2 aim to regulate protein synthesis
through eIF2α phosphorylation and cell cycle control (Hamanaka, Bennett et al. 2005).
Interestingly, in yeast GCN2 and HARS have a region of homology between them, which
in HARS is located near its catalytic core (Wek, Zhu et al. 1995). It was found that
phosphorylation of eIF2α was observed under amino acid starvation conditions,
including histidine starvation, and that HARS interacts directly with GCN2, which can
impair GCN2’s ability to phosphorylate eIF2α upon HARS mutation (Wek, Zhu et al.
1995). Additionally, uncharged tRNA molecules regulate GCN2 activity more so than the
actual amino acid starvation response (Wek, Zhu et al. 1995). Uncharged tRNA was
confirmed as the primary regulator of GCN2 in CHO-K1 cells with mutant LARS
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(Harding, Novoa et al. 2000). This finding suggests ARS involvement in a key regulatory
step that overlaps with the UPR.

1.4.3 Synthetase Involvement in ER Stress
TARS inhibition by borrelidin causes amino acid starvation, which leads to
cytotoxicity, and phosphorylation of eIF2α (Mirando, Fang et al. 2015). This indicates
that borrelidin is either triggering GCN2 activation by increasing the pool of uncharged
tRNA, or is affecting the rate of translation and inducing the UPR. In addition, borrelidin
induces caspase-3 cleavage suggesting that borrelidin may be causing apoptosis via the
PERK UPR response pathway, however this remains to be confirmed (Mirando, Fang et
al. 2015). In oral cancer cells, borrelidin was found to trigger CHOP-mediated apoptosis
indicating TARS involvement in the UPR (Sidhu, Miller et al. 2015). In this study
however, the concentration of borrelidin used and the time cells were treated with
borrelidin were both much higher than other reported literature values. This evidence
validates TARS as a potential target for UPR intervention.
It has also been reported that KARS is highly dependent on the UPR to promote
hypoxia resistance in C. elegans (Anderson, Mao et al. 2009). By transfecting with a
decrease in KARS function mutant, C. elegans shows an increase in hypoxia resistance,
which is inversely proportional to rate of translation (Anderson, Mao et al. 2009).
Additionally, hypoxia triggers the UPR, and using a dual decrease in functional
KARS/ire1 gene knockout C. elegans, this hypoxia resistance was lost (Anderson, Mao
et al. 2009). This indicates that KARS not only regulates translation rate in C. elegans,
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but can also regulate hypoxia resistance given UPR induction occurs following hypoxia
onset.

1.4.4 Monensin
Given the current connection between ARSs and the UPR, the question of what
exact mechanisms comprise this connection arises. To tease out which “flavor” of ER
stress different synthetases are involved in, different ER stressors must be examined.
Monensin is a polyether, monovalent ionophore that acts on the Na+/H+ transmembrane
pump, which subsequently collapses the Na+/H+ gradient maintained across the plasma
membrane (Mollenhauer, Morre et al. 1990). This leads to an increase in intracellular
Na+, and a subsequent increase in intracellular Ca+2 (Meral, Hsu et al. 2002). Monensin
has been linked to stimulation of exosomal release as a result of its effects on intracellular
Ca+2 concentrations (Savina, Furlan et al. 2003, Guo, Bellingham et al. 2016). In addition
to its role in exosomal release, monensin has been linked to ER stress. One study found
monensin was able to sensitize glioma cells to tumor necrosis factor-related apoptosisinduced ligand (TRAIL)-mediated apoptosis through ER stress. Monensin led to an
increase in ATF4, CHOP and p-eIF2α expression in glioma cells and decreased overall
cell viability (Yoon, Kang et al. 2013). Monensin has been used to monitor ER stress in
other studies as well (Badr, Hewett et al. 2007). Given the relatively undeveloped nature
of the mechanism by which monensin induces ER stress, experimental data of monensin
effects on synthetases would be invaluable. In the present study, we aim to further
characterize the effects that monensin has on TARS levels intracellularly and
extracellularly.
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1.5 Experimental Model
We hypothesized that the mechanism for TARS secretion from human ovarian
cancer cells was by exosomal packaging and subsequent release. We also hypothesized
that intracellular TARS expression was effected by ER stress, and that this would affect
the pro-angiogenic function of TARS. We measured TARS levels by Western blotting,
reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR),
immunofluorescence (IMF) microscopy and exosome precipitation from media and
subsequent Western blotting. We used monensin as a dual exosomal release stimulator
and ER stressor. Upon stimulation with monensin, CaOV-3 cells had higher levels of
TARS protein in the cell media compared to control, untreated cells. However when
these media samples had exosomes precipitated out there was no difference in the CD63
marker protein across samples. Monensin treatment caused TARS protein and transcript
levels to increase in CaOV-3 cells, and also induced markers of ER stress at the transcript
and protein level. Also noteworthy is we were able to show a significant increase in
VEGF transcript levels in CaOV-3 cells in response to monensin treatment. These data
indicate that CaOV-3 cells increase TARS expression and secretion in response to ER
stress.
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CHAPTER 2: EXPERIMENTAL PROCEDURES AND MATERIALS
Cell Culture
CaOV-3 human ovarian cancer cells were purchased from American tissue culture
(ATCC), and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) high glucose
(4500 mg glucose/L) (GE Healthcare or Sigma). Media was supplemented with 1% Lglutamine, 1% penicillin/streptomycin and 10% fetal bovine serum (FBS). Cells were
maintained between passages 2 and 16, and were split once they reached 70-100%
confluence. Cells were grown in 21% oxygen, 5% CO2 and 37°C in a humidified
incubator. Cell treatments were done overnight, 16-20 h, unless otherwise specified.

Reagents
Cell Culture treatments
•

Monensin (Sigma)

•

VEGF (R&D Systems)

•

Dimethyl sulfoxide (DMSO) (Fischer Bioreagents)

•

Borrelidin (Biotica Technology, LTD)

Primary Antibodies for Western Blotting
•

Rabbit anti-TARS (GeneTex #GTX116359) at 1:1000

•

Mouse anti-CD63 (Novus #NB100-77913) at 1:1000

•

Rabbit anti-β-tubulin (Cell Signaling #2128) at 1:1000

•

Rabbit anti-LARS (Protein Tech #21146-1-AP) at 1:1000
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•

Rabbit anti-AARS (GeneTex #GTX112477) at 1:1000

•

Rabbit anti-p-eIF2α (Cell Signaling #9721) at 1:1000

•

Rabbit anti-eIF4E2 (GeneTex #GTX82524) at 1:250

•

Rabbit anti-RBM4 (Protein Tech #11614-1-AP) at 1:1000

•

Rabbit anti-Hif-2α (Novus #NB100-122) at 1:1000

*All dilutions made in 3% BSA/TBST. Solutions also contain 0.1% sodium azide

Primary Antibodies for Immunofluorescence
•

Mouse anti-TARS (Abnova #H00006897-M01) at 1:200

•

Rabbit anti-TARS (GeneTex #GTX116359) at 1:200

•

Mouse anti-CD63 (Novus #NB100-77913) at 1:50

•

Rabbit anti-vimentin (Cell Signaling #5741) at 1:200

Western blotting
Cells were seeded on 10 cm plates and grown to 70-100% confluence prior to
treatment. Treatments were done in serum-free media unless otherwise specified.
Following treatment, media was collected and cell monolayers were washed in phosphate
buffered saline (PBS) (Thermo Scientific) twice, and then lysed in modified RIPA buffer
(150 mM NaCl, 50 mM Tris pH 8.0, 5 mM EDTA, 0.5% deoxycholate, 1% NP-40, 10%
glycerol; Protease inhibitors: 2 mM Na pyrophosphate (Sigma), 1 mM phenylmethane
sulfonyl fluoride (PMSF) in ethanol (Sigma), 111.17 KIU/mL aprotinin (Fischer)). Media
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was concentrated 10-fold using Amicon©-Ultra 4-Centrifugal Devices 30,000 MWCO,
and lysate was homogenized using a 25-gauge syringe. To correct for loading, a Bradford
Assay was performed on each sample for each experiment (Bradford 1976). Samples
were prepared in 4X Laemmli sample buffer (0.2 M Tris pH 6.8, 4% Sodium dodecyl
sulfate (SDS), 4 mg/mL bromophenol blue, 4% β-mercaptoethanol, 40% glycerol, 4 µM
pyronin Y), and resolved on Mini-PROTEAN TGX Stain-Free Precast Gels (Bio-Rad)
for 15-20 min at 300V. Gels were transferred to PVDF membrane for 75 min at 4°C.
Washes were done in Tris-buffered saline and Tween-20 (TBST). Blots were blocked in
3% milk in BSA/TBST for 30 min at room temperature with rocking and then incubated
in primary antibodies overnight at 4°C. Secondary antibodies used were either
horseradish peroxidase (HRP)-goat-anti-rabbit IgG (Santa Cruz) at 1:5000 or HRP-goatanti-mouse IgG (Santa Cruz) at 1:5000 in 3% BSA/TBST. Antibody-bound proteins were
detected by chemilluminescence. Blots were either developed on X-ray film or scanned
on the VersaDoc 4000 MP (BioRad) using Pierce ECL Western Blotting Substrate or
Super Signal West Femto Maximum Sensitivity Substrate (Thermo Scientific) as needed.
Bands were analyzed using Quantity One 1-D Analysis Software for densitometry
(BioRad). β-tubulin was used as a loading control.
Blots shown with multiple proteins are the same membrane reprobed with
different primary antibodies. Following chemilluminescent detection, blots were washed
in stripping buffer (1.5% glycine, 0.1% SDS, 1% Tween-20 at pH 2.2). Blots were then
reblocked and reprobed with respective primary antibodies.
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Exosome Precipitation
Cells were seeded on 10 cm plates and grown to 70-90% confluence prior to
treatment. Cells were treated using 10% FBS, exosome-depleted media (System
BioSciences). Following treatment, media was collected and exosome isolation was
performed according to manufacturer protocol. Cell lysates were not collected. Briefly,
ExoQuick-TC™ Tissue Culture Media Exosome Precipitation Solution (System
Biosciences) was added to media samples at 1 ml ExoQuick: 5 mL cell culture media.
Samples were mildly agitated and incubated for 16 h at 4°C. Following incubation,
samples were spun and the pellet, which contained exosomes, was resuspended in PBS.
These samples were frozen at -80°C, which lysed exosomes, and samples were then
resolved by Western blot. 10% FBS, exosomes-depleted media that was not exposed to
cells was resolved by Western blot as a negative control.

Immunofluorescence Microscopy
Cells were seeded on glass coverslips in a six-well plate, and grown to 90%
confluence prior to treatment. Following treatment, media was removed from the wells.
Cells were fixed in 10% formalin (Sigma-Aldrich) for 15 min at room temperature, and
then were treated with 100% methanol (Sigma-Aldrich) for 2 min at room temperature to
promote membrane permeabilization. Each slide was then incubated in a primary
antibody solution for 16 h at 4°C in a humidity box. Primary antibody solutions consisted
of Novus mouse anti-TARS and anti-vimentin in one solution and GTX rabbit anti-TARS
and anti-CD63 in another, diluted in 3% BSA/0.2% Triton X-100 (TX-100)/PBS.
Following incubation in primary antibody, wells were incubated in a secondary antibody
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solution of Alexa 488 donkey anti-mouse IgG (Invitrogen) at 1:500, Alexa 594 donkey
anti-rabbit IgG (Invitrogen) at 1:500 and 10µg/mL of 4’-6-Diamidine-2’-phenylindole
dihydrochloride (DAPI) (Roche Diagnostics) in 3% BSA/0.2% TX-100/ PBS for 1 h at
37°C in the dark. Coverslips were then mounted on Superfrost® Microscope Slides
(Fisherbrand) using Aqua Poly/Mount (Polysciences Inc.) and stored flat in the dark at
4°C prior to imaging. Slides were imaged within 1-5 days using the Nikon TE 200
inverted epifluorescence microscope from Dr. Alan Howe’s lab.

Reverse Transcriptase-quantitative Polymerase Chain Reaction (RT-qPCR)
Cells were seeded in a six-well plate, and grown to 90-100% confluence prior to
treatment. Following treatment, total RNA was extracted from cells using the RNeasy®
Plus Mini Kit (Qiagen) according to manufacturer’s instructions. Total RNA
concentration was determined using NanoDrop ND-1000 (Thermo Fischer) for each
sample. An equal mass of RNA from each sample for each trial was used to synthesize
first strand cDNA using High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems), which includes MultiScribe Reverse Transcriptase (Applied Biosystems).
RT-qPCR was performed using an ABI Prism 7900HT Sequence Detection System
(Applied Biosystems) and TaqMan® Assay Primer pairs (Applied Biosystems) for tars,
lars, aars, vegfa and dnajb9.
During the PCR reaction, Taq polymerase will knock the fluorophore off the
target gene, which emits fluorescence and is measured by the PCR detection system. The
emitted fluorescence is directly proportional to the gene expression, as measured by
threshold cycle (CT) values. Relative mRNA expression was determined using a
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comparative CT (ΔΔCT) method, and target genes were normalize to the hprt gene as the
housekeeping gene. All RT-qPCR work was performed in the University of Vermont
Cancer Center DNA Analysis Facility and was supported in part by grant P30CA22435
from the NCI.

Immunoprecipitation
Cells were seeded on 10 cm. plates, and grown to 60-80% confluence prior to
treatment. Following hypoxic treatments, cells were lysed in 1X cell lysis buffer (CLB)
(20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% TX-100; Protease
inhibitors: 2.5 mM Na pyrophosphate, 1 mM Na orthovanadate, 1 µg/mL leupeptin, 1
mM PMSF in EtOH, 1 µg/mL aprotinin), and lysates were homogenized using a 25gauge syringe. TARS protein was pulled down from solutions using Dynabeads® M-280
Sheep anti-Mouse IgG (Thermo Fischer) bound to Novus mouse anti-TARS antibody.
Protein bound to the beads was eluted off in Laemmli 4XSB and high heat. Total lysate,
supernatant following the pull down and protein eluted from the beads was resolved by
Western blot for each sample. The “no antibody control” refers to a sample that was
exposed to Dynabeads that were not bound to Novus mouse anti-TARS antibody. This
sample should not have any TARS or associated proteins in the pull down.

Separation of Nuclear Cell Lysate from Cytoplasmic Cell Lysate
Cells were seeded on 10 cm plates and grown to 90% confluence. Following
treatments, media was removed, and cells were lysed in hypotonic lysis buffer (1 M Tris
pH 8.0, 1 M MgCl2, 2 M KCl; Protease inhibitors: 100 mM PMSF in EtOH, 2 mg/mL
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Aprotinin, 2 mM Na Pyrophosphate). Total cell lysate was spun at 1000 x g, 5 min,
which pellets the nuclear fragment. Cytosolic supernatant was removed, and the nuclear
pellet was washed in hypotonic lysis buffer. The pellet was resuspended in hypotonic
lysis buffer. Samples were resolved by Western blot.
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CHAPTER 3: EXTRACELLULAR TARS PROTEIN LEVELS INCREASE IN
CAOV-3 CELLS IN RESPONSE TO MONENSIN TREATMENT WHILE CD63
PROTEIN IS UNAFFECTED
3.1 Introduction

SKOV-3 cells, a human ovarian cancer cell line, overexpress TARS and show
colocalization of TARS with pro-angiogenic markers (Wellman, Eckenstein et al. 2014).
This renders human ovarian cancer cells as a valid in vitro model to study TARS and its
effects on angiogenesis. TARS also promotes angiogenesis and cell migration
extracellularly in endothelial cells (Williams, Mirando et al. 2013). We hypothesize that
TARS is secreted from cells via exosomal release, as there is evidence for synthetase
protein and mRNA packaging in exosomes (Liang, Peng et al. 2013, Wang, Xu et al.
2013). To test for this we used an exosome stimulator, monensin, as a means to increase
TARS secretion from CaOV-3 cells.

3.2 Results
To first test the hypothesis that monensin stimulates TARS secretion, we
performed Western blots on concentrated cell media from CaOV-3 cells treated with
monensin compared to control. Upon treatment with 10 µM monensin, TARS protein
levels increased in the cell media compared to a DMSO control (Fig. 4). The stock
solution of monensin was dissolved in DMSO, and so DMSO was used as the control
treatment to ensure all cell plates received equal volumes of DMSO. DMSO increases the
permeability of lipid membranes, and so it is important to maintain experimental groups
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in equal volumes of DMSO (Notman, Noro et al. 2006). This initial finding confirms that
monensin is causing TARS protein levels to increase in the cell media.

Figure 4: TARS is secreted out of CaOV-3 cells in response to monensin treatment.
Western blot of concentrated cell media using an antibody against TARS. Cells were
treated in serum-free media with respective reagents for 16 h before media was collected.
Media samples were concentrated 12-fold. Blot was not quantified, but this result was
duplicated.

With knowledge that TARS protein levels increased in CaOV-3 cell media
following treatment with monensin, we next wanted to determine if the extracellular
TARS we were detecting was packaged in exosomes. CaOV-3 cells were treated in 10%
FBS, exosome-depleted media. Cell media was incubated with ExoQuick-TC™ solution,
which precipitates exosomes out of solution. The exosome precipitant was pelleted, and
resuspended in PBS. Samples were then resolved by Western blot and anti-TARS and
anti-CD63 antibodies were used to detect protein (Fig. 5A). CD63 is an exosomal marker
protein that is expressed on ovarian cancer-derived exosomes as well as breast cancerderived exosomes (Gercel-Taylor, Atay et al. 2012, King, Michael et al. 2012). We found
that monensin and VEGF treatments both led to an increase in extracellular TARS
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protein following exosome precipitation compared to the DMSO control (Fig. 5C),
however this increase does not correspond to a change in CD63 protein levels (Figs. 5B).
This confirms our initial result regarding increased levels of extracellular TARS protein
in response to monensin treatment, and shows that extracellular TARS protein levels also
increase in response to VEGF in CaOV-3 cells, similar to prior results in endothelial cells
(Williams, Mirando et al. 2013). However, we fail to show extracellular TARS is
secreted in exosomes. These trends did not match statistical significance.
IMF microscopy staining for CD63 further confirmed that neither monensin nor
VEGF treatment of CaOV-3 cells causes an increase in CD63 protein levels. These
images represent intracellular TARS and CD63. Monensin and VEGF both failed to
cause an increase in intracellular CD63 (Fig. 6). The CD63 staining pattern is “spotted”
and localized throughout the cytoplasm, which aligns with expected MVB distribution
(Pols and Klumperman 2009). It can be assumed that the anti-CD63 antibody is marking
exosomes that are either destined for secretion, or are being endocytosed from the
extracellular space. In addition, intracellular TARS protein increases in CaOV-3 cells
when treated with monensin or VEGF (Fig. 6). These results further our claim that
monensin and VEGF treatments increase TARS protein levels, however this increase is
not coupled with an increase in CD63 protein. The mechanism of TARS secretion
therefore remains unresolved.
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Figure 5: TARS protein secretion increases with monensin and VEGF cell
treatments while CD63 is unaffected. (A) Western blot of exosomes precipitated out of
cell media using antibodies against TARS and CD63. CaOV-3 cells were treated in
exosome-depleted media and respective reagents. Cell media was collected and exosomes
were precipitated out of solution using ExoQuick-TC™. A sample of exosome-depleted
media was run as a negative control. The banding pattern on the lower blot was only
observed in this trial, while the band indicated as CD63 could be replicated. CD63 is
between 26-60 kD depending on its glycosylation state, which is why all three bands are
shown. (B,C) Quantification of CD63 (B) and TARS (C) protein levels normalized to the
negative control; mean±SEM, n=3, p>0.05 comparing experimental groups and negative
control and comparing 10 µM monensin and 50 ng/ml VEGF treatments with DMSO
control (Kruskal-Wallis, Dunn’s multiple comparisons test).
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Fig. 6: Monensin and VEGF treatments of CaOV-3 cells do not affect intracellular
CD63 protein levels. CaOV-3 cells were grown on glass cover slips and treated in 10%
FBS. Cells were treated with DMSO, 10 µM monensin or 50 ng/mL VEGF for 18h. Cells
were fixed with 10% formalin and stained with DAPI, rabbit anti-TARS and mouse antiCD63 antibodies. DAPI, TexasRed and FITC channels were used to acquire images.
We conclude that both monensin and VEGF increase the extracellular
concentration of TARS protein in CaOV-3 cells, however this increase is not confirmed
to be a result of exosomal release. Although there is an increase in CD63 protein
compared to the negative control (Fig. 5B), there is no increase when comparing
monensin- or VEGF-treated cells to DMSO-treated cells. This confirms the presence of
exosomes in experimental samples, but fails to confirm our hypothesis. Therefore, TARS
protein levels increase extracellularly in response to either monensin or VEGF, but the
mechanism of secretion remains unresolved.
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CHAPTER 4: INTRACELLULAR TARS LEVELS IN CAOV-3 CELLS ARE
AFFECTED BY MONENSIN TREATMENT
4.1 Introduction

Many ARS genes are downstream targets of ATF4 and CHOP transcription
factors in the UPR (Han, Back et al. 2013). This exemplifies how the maladaptive ER
stress response induces transcriptional regulation of protein synthesis. TARS inhibition
by borrelidin triggers the PERK maladaptive UPR through phosphorylation of eIF2α, and
cleavage of caspase-3 (Mirando, Francklyn et al. 2014). This shows further induction of
the UPR by disruption of protein synthesis. Here we wanted to investigate how ER stress
that is separate from TARS inhibition affects TARS protein and transcript levels in
ovarian cancer cells.

4.2 Results

First we observed how intracellular TARS protein levels were affected in CaOV-3
cells following monensin treatment. CaOV-3 cells were treated with either DMSO or 10
µM monensin in serum-free media, and total cell lysates were resolved by Western blot.
We probed these blots with anti-TARS, anti-LARS and anti-AARS antibodies (Fig. 7A).
LARS and AARS were used to test whether results we observed with TARS were TARSspecific, or whether these results could be extended to other synthetase proteins.
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Fig. 7: TARS protein increases intracellularly in response to monensin by Western
blot. (A) Western blot of total cell lysates from CaOV-3 cells treated with respective
reagents using antibodies against TARS, LARS and AARS. (B-D) Quantified protein
values for TARS (B), LARS (C) and AARS (D) relative to a β-tubulin loading control.
Samples were normalized to DMSO; mean±SEM, n=4, p>0.05 comparing 10 µM
monensin and DMSO (Wilcoxon signed-rank test).

We observed that in CaOV-3 cells, monensin induced an increase in expression of
intracellular TARS protein (Fig. 7B), although the consistent trend did not match
statistical significance. LARS protein levels did not change in response to monensin (Fig.
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7C), and AARS protein levels decreased (Fig. 7D). More experimental trials would be
necessary to confirm this result, and gain statistical significance. The lack of significance
may also owe to the inconsistent nature of Western blotting.
This result shows that TARS protein levels increase in response to an ER stressor
that does not inhibit synthetase activity. The increase in TARS and not LARS or AARS
indicates TARS protein is playing a specific role in response to ER stress separate from
global synthetase expression. Interestingly, monensin caused AARS protein levels to
decrease.
Intracellular TARS increasing in response to monensin was also observed by IMF
microscopy. CaOV-3 cells treated in both 0.1% FBS and 10% FBS (low and high serum,
respectively) media exhibit an increase in TARS staining with monensin treatment (Figs.
8A-B). This increase is not seen following VEGF treatment. Vimentin is a common
intermediate filament expressed in mesenchymal cells, which has recently been found to
be overly expressed in tumor cells and to be a good marker of epithelial-to-mesenchymal
transition (Eriksson, Dechat et al. 2009, Satelli and Li 2011). We did not expect vimentin
expression to change in response to either monensin or VEGF, and so it was used here to
confirm cytoplasmic integrity. There is a clear increase in TARS staining with monensin
treatment, and this increase is most apparent in the low serum-treated cells (Fig. 8A).
Low serum and monensin both highly stress the cells, which is correlated with an
increase in TARS protein expression. TARS protein is localized in the cytoplasm with
punctate structures distributed throughout.
We also found that monensin treatment decreased DAPI staining in both low and
high serum-treated cells compared to DMSO controls, although the decrease was more
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pronounced in low serum (Figs. 8A-B). DAPI stains cell nuclei, which confirms cell
integrity upon formalin fixing. This indicates that cell death occurred as a result of
monensin treatment, as cells were grown to equal confluence prior to treatments.
However, even with the decrease in DAPI staining, monensin still caused an
increase in TARS staining. Taken together with the Western blots of concentrated CaOV3 cell media (Fig. 4) and CaOV-3 total cell lysates (Fig. 7A), these data indicate that the
observed increases in TARS protein in response to monensin treatment are a result of
increased TARS expression, and not uncontrolled detection due to cell death.
Intracellular TARS protein localizes in the cytoplasm of CaOV-3 cells regardless
of treatment (Fig. 9). This aligns with the literature, which reports TARS localization in
both the cytoplasm and the mitochondria of the bacterium T. brucei (Kalidas, Cestari et
al. 2014). TARS localization in the cytoplasm was observed by both IMF microscopy
(Fig. 8) and by Western blot (Fig. 9). We therefore conclude that ER stress stimulated by
monensin does not affect TARS localization.
To assess whether TARS induction by monensin was at the level of gene
transcription, its effect on TARS and other ARS mRNA transcript levels was
investigated. Transcript levels in CaOV-3 cells were quantified using RT-qPCR
following respective treatments. Probes for AARS and LARS were used to test whether
or not the TARS response was TARS-specific or if it was a general synthetase response.
Following monensin treatment, TARS transcript levels increased 2-fold (Fig.
10B). To confirm ER stress at the transcript level, DNAJB9 mRNA was quantified.
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Fig. 8: Monensin-treated CaOV-3 cells have increased intracellular TARS by IMF
microscopy. (A, B) CaOV-3 cells were grown on glass cover slips and treated with either
0.1% FBS (A) or 10% FBS (B) and either DMSO, 10 µM monensin or 50 ng/mL VEGF
for 18h. Cells were fixed with 10% formalin and stained with DAPI, mouse anti-TARS
and rabbit anti-vimentin antibodies. DAPI, TexasRed and FITC channels were used to
acquire images.
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Fig. 9: TARS localizes to the cytoplasm of CaOV-3 cells. CaOV-3 cells were serumstarved and treated with DMSO, 50 ng/mL VEGF or 10 µM monensin. Cells were lysed
and nuclear and cytoplasmic lysates were separated and resolved by Western blot. A
primary antibody against TARS was used. Anti-β-tubulin and anti-lamin A/C primary
antibodies were used as loading control for cytoplasmic and nuclear fractions,
respectively (not shown).
DNAJB9 is a member of the DNAJ protein family, which act as accessory proteins to
regulate the 70 kD heat shock protein family (Hsp70) (Shen, Meunier et al. 2002).
Specifically, DNAJB9 localizes to the ER where it regulates the heat shock protein BiP,
and has been found to combat cell death induced by ER stress (Shen, Meunier et al. 2002,
Kurisu, Honma et al. 2003). DNAJB9 has also been found to interact with p53 protein,
and act as an inhibitor of p53-induced apoptosis (Lee, Kim et al. 2015). We found that
monensin caused DNAJB9 mRNA levels to increase 2-fold in CaOV-3 cells (Fig. 10A).
VEGF treatment did not induce an increase in either DNAJB9 or TARS transcript levels
(Figs. 10A-B). These data show that monensin is inducing ER stress, which is
subsequently causing TARS transcript levels to increase.
Monensin treatment did not cause LARS transcript levels to increase (Fig. 10C),
but did cause AARS transcript levels to increase 2-fold, similar to TARS transcript (Fig.
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10D). VEGF treatment did not affect either LARS or AARS transcript levels. The
increase in AARS transcript levels in response to monensin suggests that the synthetase
transcript induction by ER stress may not be a TARS-specific response. This result could
be indicative of the ARS family’s role in total protein synthesis. However, LARS
transcript does not increase in response to monensin treatment, and so the ER stressinduced synthetase transcript increase is not a family-wide response.
VEGF transcript levels increase 6-fold in response to monensin treatment (Fig.
10E). The increase in VEGF transcript suggests a pro-angiogenic response by CaOV-3
cells in response to monensin. It is unknown how this increase in VEGF transcript may
be affecting TARS protein or transcript. However, we show that CaOV-3 cells exhibit a
pro-angiogenic response that is coupled with an increase in TARS and AARS transcript
levels following ER stress by monensin.
All transcript values discussed above are referring to the 0.1% FBS-treated cells.
These cells were exposed to the additional stress of being treated in low serum media.
Interestingly, DNAJB9 transcript levels increase slightly more in high serum-treated cells
treated with monensin compared to low serum, monensin-treated cells.
These data confirm monensin is causing ER stress in CaOV-3 cells. TARS and
AARS transcript levels both have a 2-fold increase in response to ER stress induced by
monensin, while VEGF transcript levels increase 6-fold. Statistical significance was
obtained for all monensin treated groups compared to the DMSO control within the
respective serum level.

44

Fig. 10: Changing mRNA expression levels in CaOV-3 cells in response to ER stress.
(A-E) RT-qPCR values for DNAJB9 (A), TARS (B), LARS (C), AARS (D) and VEGF
(E) were measured. CaOV-3 cells were incubated in either 0.1% or 10% FBS for 18h. In
addition, cells were treated with either DMSO, 10 µM monensin or 50 ng/mL VEGF.
Total RNA was extracted using a Qiagen RNeasy® Mini Kit and expression levels were
determined using the ΔΔCT method relative to the hprt gene as a housekeeper. Values
were normalized to 0.1% FBS, DMSO-treated cells; mean±SEM, n=4, *p≤0.0008,
**p<0.015 relative to DMSO at respective [FBS] (Two-way ANOVA).
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With knowledge that monensin was inducing ER stress, we next wanted to
determine if titration of increasing monensin concentrations onto CaOV-3 cells would
cause an increase in intracellular TARS protein that correlates with increased ER stress.
CaOV-3 cells were treated with 0 µM-10 µM monensin with a logarithmic increase.
TARS, LARS, AARS and p-eIF2α protein levels were determined by Western blot (Figs.
11A-B). TARS protein levels increased accordingly with increasing monensin
concentrations (Fig. 11C). A similar pattern of increase was observed in p-eIF2α protein
levels (Fig. 11F). These data indicate that TARS protein levels and UPR induction are
correlated upon treatment with monensin, and both increase as the concentration of
monensin increases. These trends did not match statistical significance, and so further
trials are required to confirm our results.
LARS and AARS protein levels did not show a clear increase that corresponded
to increasing monensin concentration (Figs. 11D-E). The lack of correlation between
monensin concentration and LARS and AARS protein levels further suggests that the
CaOV-3 cell response to ER stress by monensin at the level of synthetase proteins is
TARS-specific.
TARS and p-eIF2α protein levels both increase in CaOV-3 cells as monensin
concentration increases indicating a correlation between ER stress induction and TARS
protein expression. This dose-response effect was found to be TARS-specific, as LARS
and AARS protein levels did not exhibit a similar monensin concentration-dependent
increase. Due to the lack of statistical significance and the high error in this experiment,
these conclusions are solely based on trends.
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Fig. 11: TARS and p-eIF2α protein levels increase in response to increasing
monensin. CaOV-3 cells were treated in serum-free media and respective concentrations
of monensin. Total cell lysates were resolved by Western blot and primary antibodies
were used against TARS, LARS, AARS and p-eIF2α. (A, B) Two representative blots are
shown for TARS, LARS and AARS (A) and for p-eIF2α (B) proteins. (C-F) TARS (C),
LARS (D), AARS (E) and p-eIF2α (F) protein levels were quantified relative to β-tubulin
and normalized to 0 µM monensin; mean±SEM, n=3, p>0.05 comparing experimental
groups and 0µM monensin (Kruskal-Wallis, Dunn’s multiple comparisons test).
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These results were furthered by examining transcript levels in CaOV-3 cells in
response to increasing monensin concentrations. TARS transcript levels increased
accordingly with increasing monensin concentrations (Fig. 12B). TARS transcript levels
increased 2-fold with 10 µM monensin, which agrees with earlier RT-qPCR data (Fig.
10B). DNAJB9 transcript levels also exhibit a dose-dependent increase with increasing
monensin concentration (Fig. 12A), however this increase is less pronounced than the
increase in TARS. These data suggest that TARS is increasing at the transcript level as
the ER stress response increases in strength.
LARS transcript levels increase following monensin treatment, however this
increase does not correlate to monensin concentration (Fig. 12C). In contrast, AARS
transcript levels increase accordingly with increasing monensin concentration (Fig. 12D).
Similar to prior RT-qPCR results (Figs. 10B and D), TARS and AARS transcript levels
in CaOV-3 cells show similar trends in response to monensin. Therefore, the ARSs seem
to respond to monensin at the mRNA level differently than at the protein expression
level, and this transcript response is not TARS-specific.
VEGF transcript levels show a clear increase that corresponds to increasing
monensin concentrations (Fig. 12E). This furthers the argument that CaOV-3 cells
become pro-angiogenic following ER stress by monensin. Following 10.0 µM monensin
treatment of CaOV-3 cells, VEGF transcript levels increase 4-fold (Fig. 12E) while
TARS transcript levels increase 2-fold (Fig. 12B). Both of these increases are statistically
significant. Therefore, the VEGF transcript response to monensin is more strongly
induced than the TARS transcript response in CaOV-3 cells.
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ER stress by monensin shows minor increase at the DNAJB9 transcript level as
increasing concentrations of monensin are applied to CaOV-3 cells. TARS and AARS
transcript levels increase in correlation with increasing monensin concentrations,
indicating that the ARS transcript response to ER stress is likely not TARS-specific.
These ARS transcript data agree with earlier results (Fig. 10). The value for TARS
mRNA in CaOV-3 cells following 10 µM monensin treatment (Fig. 12B), however, was
the only synthetase transcript value that had statistical significance. The VEGF transcript
levels showed a clear, dose-dependent increase in response to increasing monensin
concentrations, which furthers the claim that monensin promotes a pro-angiogenic tumor
microenvironment.
Next we wanted to test the effects of borrelidin, a known inhibitor of TARS and
ER stress inducer, on CaOV-3 cells’ protein and transcript levels (Mirando, Fang et al.
2015). CaOV-3 cells were treated with monensin, borrelidin or monensin and borrelidin,
and protein and transcript levels were quantified. Monensin and borrelidin were both
used at 1.0 µM for treatments. Whole cell lysates were resolved by Western blot and
probed with anti-TARS, anti-LARS and anti-AARs antibodies (Fig. 13A) and an anti-peIF2α antibody (Fig. 13B).
We found that borrelidin decreased TARS protein expression compared to
monensin treatment, and monensin and borrelidin treatment yielded slightly higher TARS
protein expression compared to borrelidin treatment (Fig. 13C). This result confirms
monensin is increasing TARS protein expression, and shows that borrelidin is
suppressing TARS protein expression.
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Fig. 12: TARS and VEGF transcript levels increase in response to increasing
monensin. (A-E) RT-qPCR results for monensin titration onto CaOV-3 cells probing for
DNAJB9 (A), TARS (B), LARS (C), AARS (D) and VEGF (E). Cells were treated with
respective concentrations of monensin for 16 h in 0.1% FBS media, and total RNA was
extracted using a Qiagen RNeasy® Mini Kit. Expression levels were determined using
the ΔΔCT method relative to the hprt gene as a housekeeper. Values were normalized to
0 µM monensin; mean±SEM, n=3, *p<0.05 relative to 0 µM monensin (Kruskal-Wallis,
Dunn’s multiple comparisons test).
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Borrelidin treatment of CaOV-3 cells induces the UPR as expected, which can be
observed by the large spike in p-eIF2α protein expression compared to untreated cells
and monensin-treated cells (Fig. 13F). Interestingly, combined treatment with borrelidin
and monensin caused a decrease in p-eIF2α protein levels compared to the borrelidin
treatment.
LARS protein levels decrease in response to borrelidin (Fig. 13D), similar to
TARS protein, while AARS protein levels remain relatively unaffected in response to
borrelidin treatment (Fig. 13E). Therefore, it is likely that the decrease in TARS protein
expression resulting from borrelidin treatment is independent of TARS inhibition.
Borrelidin elicits a strong ER stress response, which is apparent from the dramatic
increase in p-eIF2α protein levels seen in CaOV-3 cells following borrelidin treatment.
TARS protein levels decrease in response to borrelidin when compared to monensin
treated cells, which suggests monensin and borrelidin are causing ER stress via separate
mechanisms. No quantified protein values were statistically significant. To confirm these
results more experimental trials would need to be performed. To further this experiment,
we could look at how synthetases are modified in response to borrelidin treatment, and
how these modifications may affect their function.
Borrelidin treatment of CaOV-3 cells had a more dramatic effect on transcript
levels than it did on protein levels. Borrelidin’s ER stress response was again clear at the
transcript level. DNAJB9 transcript levels increased 2-fold in response to borrelidin
treatment (Fig. 14A). DNAJB9 mRNA was not highly affected by monensin treatment at
1.0 µM.
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At the transcript level, borrelidin led to a 4-fold increase in TARS (Fig. 14B) and
AARS (Fig. 14D), and a 2.5-fold increase in LARS (Fig. 14C) compared to the DMSO
control. This shows that the cell increases transcription rates of synthetases upon ER
stress induction by borrelidin. Monensin and borrelidin dual treatment yields synthetase
transcripts levels that are similar to just borrelidin treatment.
VEGF transcript levels increase 11.5-fold in CaOV-3 cells in response to
borrelidin treatment, and 15-fold in response to borrelidin and monensin dual treatment
(Fig. 14E). This suggests that borrelidin and monensin both cause ovarian cancer cells to
become pro-angiogenic intracellularly. Given the abundance of VEGF transcripts
following borrelidin and monensin treatments, it could be hypothesized that the cells
utilize α6β4 integrin signaling to gain angiogenic activity under ER stress (Fig. 1).
Borrelidin induces ER stress, as is apparent by the increase in p-eIF2α protein
(Fig. 13F) and DNAJB9 transcript (Fig. 14A) in CaOV-3 cells. Similarly, monensin
treatment causes an increase in p-eIF2α protein that correlates with increasing monensin
concentration (Fig. 11F). However, the mechanism of ER stress caused by borrelidin is
different from that caused by monensin. Whereas monensin treatment causes an increase
in TARS protein in a dose-dependent manner (Fig. 11C), borrelidin decreases TARS
protein levels compared to monensin treatment (Fig. 13C). At the transcript level, both
borrelidin and monensin elicit an increase in TARS transcript levels (Figs. 12B and 14B).
In addition, borrelidin treatment causes a large increase in LARS and AARS transcript
levels (Figs. 14C-D). Again, TARS and AARS transcript levels exhibit similar trends
following cell treatment. Finally, borrelidin and monensin both induce an increase in
VEGF transcript levels (Figs. 12E and 14E). Taken together, these data begin to suggest
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what mechanism monensin is inducing the UPR by, and what affect that has on TARS
and other synthetases.

Fig. 13: Borrelidin treatment causes p-eIF2α protein to increase but not TARS
protein. CaOV-3 cells were treated in serum free media and respective reagents.
Borr.=borrelidin; Mon.=monensin. DMSO served as the control treatment, and borrelidin
and monensin were both used at 1.0 µM. Total cell lysates were resolved by Western blot
and primary antibodies against TARS, LARS, AARS and p-eIF2α were used. (A, B) Two
representative blots are shown for TARS, LARS and AARS (A) and p-eIF2α (B)
proteins. (C-F) TARS (C), LARS (D), AARS (E) and p-eIF2α (F) protein levels were
quantified relative to β-tubulin and normalized to DMSO. Monensin-only treated values
are from the blots in Fig. 11; mean±SEM, n=3, p>0.05 comparing experimental groups
and DMSO (Kruskal-Wallis, Dunn’s multiple comparisons test).
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Fig. 14: Transcript levels increase in response to borrelidin and monensin
treatments. (A-E) RT-qPCR results for borrelidin (Borr.) and monensin (Mon.)
treatments onto CaOV-3 cells probing for DNAJB9 (A), TARS (B), LARS (C), AARS
(D) and VEGF (E). Borrelidin and monensin were both used at 1.0 µM. DMSO was used
as a control treatment. Cells were treated for 16 h in 0.1% FBS media and total RNA was
extracted using a Qiagen RNeasy® Mini Kit. Expression levels were determined using
the ΔΔCT method relative to the hprt gene as a housekeeper. Values were normalized to
DMSO; mean±SEM, n=3, *p<0.05 relative to DMSO (Kruskal-Wallis, Dunn’s multiple
comparisons test).
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4.3 Conclusion

We are able to show that monensin serves as a valid experimental tool in further
deciphering non-canonical functions of TARS both extracellularly and as a participant in
the UPR in ovarian cancer cells. Monensin stimulates TARS secretion from CaOV-3
cells, however the mechanism of TARS secretion remains undefined. Additionally,
monensin causes TARS protein and transcript levels to increase intracellularly. LARS
and AARS protein levels and LARS transcript levels are affected inconsistently by
monensin treatment. AARS transcript levels show a correlation to TARS transcript levels
in response to monensin treatment. VEGF transcript levels are also increased
significantly with monensin treatment of CaOV-3 cells. We confirm that monensin
induces ER stress, and that the mechanism by which it stimulates the UPR likely differs
from borrelidin UPR induction. Together these data yield insight into the role TARS
plays in promotion of cancer cell survival.
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CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS

5.1 Monensin as a Novel Model to Study TARS

5.1.1 Molecular Effects of Monensin
In this study we show that monensin treatment of ovarian cancer cells provides
both a novel approach for studying TARS secretion, and for studying TARS expression
in response to ER stress. Given the pro-angiogenic function of extracellular TARS in
endothelial cells (Williams, Mirando et al. 2013), it is important to discern what
molecular conditions affect TARS levels intracellularly and how TARS is being secreted.
Studying TARS in a cancer model begins to expand the angiogenic potential of TARS.
We provide evidence that monensin stimulates TARS secretion (Fig. 4), however the
precise mechanism of secretion remains unresolved. We also show evidence that
monensin promotes ER stress, and that TARS protein and transcript expression increases
following monensin treatment. Although monensin is not widely found in nature, its
effects on ovarian cancer cells with respect to TARS expression have yielded valuable
information.
Monensin is an ionophore that disrupts the Na+/H+ gradient across the plasma
membrane. In our experimental model we initially used monensin to increase exosome
production, however the observation that monensin causes ER stress provides a clue to its
other possible effect on cells. Not only has monensin been found to sensitize glioma cells
to TRAIL-mediated apoptosis (Yoon, Kang et al. 2013), but monensin was also found to
induce oxidative stress and apoptosis in prostate cancer cells, and to inhibit growth
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through cell cycle arrest and apoptosis in lymphoma and renal carcinoma cells (Park,
Seol et al. 2002, Park, Jung et al. 2003, Ketola, Vainio et al. 2010). The link to apoptosis
raises concern over whether or not the detected extracellular TARS protein was a result
of secretion.
Apoptotic cells have distinct changes in their morphology referred to as
“apoptotic bodies” that bleb off from the cell membrane, and are ultimately engulfed and
destroyed by macrophages (Elmore 2007). This event does not result in an inflammatory
response. Apoptosis is different from necrosis, which is another form of cell death where
the cell membrane integrity is disrupted and the cell spills its contents into the
extracellular space eliciting an inflammatory response (Elmore 2007). Since monensin
has been specifically linked with apoptosis and not necrosis in carcinoma cells, we
conclude that the TARS increase in the cell media of cultured CaOV-3 cells was a result
of secretion. However, it is important to recognize that apoptotic cells experience
dysfunctional mitochondria and a homeostatic imbalance. An alternative mechanism that
arose from side effects of apoptosis could have played a role in the increase in
extracellular TARS protein.

5.1.2 Exosome Detection
In the present study, we were unable to confirm that the detected extracellular
TARS protein was secreted via exosomal release (Fig. 5). There are many methods for
exosome purification and detection, and choosing the proper one has proved challenging
for many researchers. Issues surrounding exosome isolation include avoiding aggregates
(more than one particle stuck together), ensuring vesicles that fall within the size range of
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40-100 nm have been purified, and labeling exosomes with biomarkers for detection. One
common method for purifying exosomes is by ultracentrifugation (Thery, Amigorena et
al. 2006). Other methods include separation of samples on a density gradient or by
affinity chromatography (Greening, Xu et al. 2015), These methods, however, can lead to
shearing of exosomes and incomplete separation. We isolated exosomes using a
polyethylene glycol (PEG)-based reagent that creates a hydrophilic environment in
solution, and allows for precipitation of exosomes upon low speed centrifugation. Using
volume-excluding polymers like PEG has been shown to effectively purify exosomes as
aggregates (Lane, Korbie et al. 2015, Weng, Sui et al. 2016).
Currently there is little uniformity in standards for detection of exosomes. Some
common methods of detection are transmission electron microscopy to actually visualize
exosomes, tagging exosome-bound proteins with biomarkers or beads and detecting by
flow cytometry, resolving samples by Western blot and probing for exosomal marker
proteins and detection with a nanoparticle analyzer. Several of these techniques have
been used to detect cancer cell-derived exosomes (Welton, Khanna et al. 2010, Peinado,
Aleckovic et al. 2012). Nanoparticle detection devices are the gold standard, as they can
accurately yield particle size and concentration as well as detect fluorescence.
Given the wide range of options for detecting exosomes, our original hypothesis
should be revisited. The isolation technique of exosomes from CaOV-3 cells seemed to
efficiently purify exosomes (Fig. 5B), however our detection method relied too heavily
on immunoreactivity, which ultimately yielded inconsistent and likely inaccurate results.
We were able to detect nanoparticles from CaOV-3 cells on a NanoSight (Malvern) for
one trial (Table 1.A). Since we are concerned with TARS packaging in exosomes, using
58

the NanoSight to detect fluorescent TARS in exosome fractions would be useful as well.
Exosomal release is a primary mechanism cells use to send biochemical signals to other
cells, and so it remains likely that the extracellular, pro-angiogenic function of TARS is
enabled by exosomal release.

5.2 Post-Translational Modifications

5.2.1 Palmitoylation
Chemical modifications of TARS may alter its localization and intracellular
function, which could influence its extracellular role. Post-translational modifications
(PTMs) are chemical additions to side chains of specific protein residues that alter
biological function. TARS gets phosphorylated and acetylated, two common PTMs,
which affects its function and localization in the cell (Choudhary, Kumar et al. 2009,
Zhou, Di Palma et al. 2013). Another PTM is protein palmitoylation. Palmitoylation is
the reversible, covalent attachment of a palmitic acid moiety to the side chain of cysteine
residues (Aicart-Ramos, Valero et al. 2011). The reversibility of this modification enables
palmitoylated proteins to localize to different areas of the cell through subcellular
trafficking (Aicart-Ramos, Valero et al. 2011). This added localization function results
from an increase in hydrophobicity, and ability to anchor into lipid membranes. N-Ras
and H-Ras are two well-characterized proteins that utilize palmitoylation and
depalmitoylation to traffic between the ER, the Golgi apparatus and the plasma
membrane via vesicular transport (Linder and Deschenes 2007, Aicart-Ramos, Valero et
al. 2011).
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Initially we hypothesized that TARS palmitoylation facilitated its packaging into
exosomes. Preliminary data testing the effects of monensin on TARS palmitoylation was
inconclusive, and therefore is not shown here. Given our current hypothesis that TARS is
secreted by exosomal release, testing for TARS palmitoylation would yield insight into
how TARS may be packaged in exosomes. Using a Group-based prediction system
algorithm that predicts protein palmitoylation sites based on protein sequence found here,
http://lipid.biocuckoo.org/index/php, we found that TARS is likely to be palmitoylated at
C137, C254 and C630. The TARS sequence was found at www.unitprot.org, Human
Threonine tRNA Ligase, cytoplasmic (#P26639). By synthesizing plasmids with
respective cysteine residues mutated, and transfecting these plasmids into CaOV-3 cells,
we could compare WT TARS with cysteine-mutant TARS. We expect that mutating
these cysteine residues would block TARS palmitoylation and subsequently would block
TARS secretion in response to VEGF, TNF-α or monensin, and would inhibit the proangiogenic function of TARS. Of note, there is evidence that tetraspanin proteins,
exosome membrane localized proteins including CD63, are palmitoylated, which
influences their association with other cell surface tetraspanins (Yang, Claas et al. 2002).
Post-translationally modified proteins often have increased protein-protein interactions.

5.2.2 The Ubiquitin Family of Modifications
While palmitoylation is a small PTM, ubiquitin and ubiquitin-like modifications
comprise a family of large peptide PTMs that modulate many different biological
processes. Modification with ubiquitin has historically been associated with targeting to
the proteasome, although alternative roles for this PTM have begun to emerge (Schwartz
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and Hochstrasser 2003). Additionally, several ubiquitin-like protein modifications have
been uncovered. SUMOylation refers to addition of a small ubiquitin-like modifier
(SUMO) peptide to lysine residues typically following cell stress (Hay 2005).
SUMOylation is a highly regulated process in eukaryotes, and has been found to
participate in various proliferative events including cell cycle control, transcription
regulation and chromatin organization (Schwartz and Hochstrasser 2003, Hay 2005).
TARS has SUMOylation sites as revealed by large scale human proteome analyses,
which raises the question of what conditions would cause TARS to become SUMOylated
and how would TARS protein primary and secondary functions be affected in response to
SUMOylation (Becker, Barysch et al. 2013, Hendriks, Lyon et al. 2017, Lamoliatte,
McManus et al. 2017).
To study TARS SUMOylation experimentally, treating human cells with MG132
would be useful. MG132 has a structure that mimics a small peptide (Fig. 15A) and
inhibits protein turnover following protein synthesis through inhibition of the
proteasome. In HEK293 cells, it has been reported that treatment with MG132
significantly increases protein SUMOylation including ribosomal and proteasomal
elements, which get localized to the nucleus (Lamoliatte, Caron et al. 2014). MG132 also
generates reactive oxygen species, and has been linked with apoptosis in tumor cells, two
downstream UPR effects (Han, Moon et al. 2009, Guo and Peng 2013). The combined
ability of MG132 to promote SUMOylation and stimulate maladaptive UPR responses
would allow us to observe whether TARS is SUMOylated during ER stress.
We report here that TARS protein expression decreases following borrelidin
treatment (Fig. 13C) and TARS transcript levels increase following borrelidin treatment
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(Fig. 14B) in CaOV-3 cells. Combined, these results suggest an increase in protein
turnover and a decrease in protein stability. Therefore, we believe that TARS may be
ubiquitinylated in response to ER stress by borrelidin. In contrast, monensin increases
TARS protein (Figs. 7B and 11C) and transcript (Figs. 10B and 12B) in CaOV-3 cells.
This result indicates that protein turnover rate is not increasing in response to monensin.
Monensin elicits ER stress, although not as strongly as borrelidin, as revealed by p-eIF2α
induction (Fig. 13F). Therefore, if monensin is stimulating PTM of TARS, it is likely not
ubiquitinylation. However given the induction of the UPR by monensin coupled with the
increased TARS expression, it is possible that TARS gains a PTM that enables it to
interact with UPR elements.
For future experiments, it would be useful to compare the effects of MG132,
monensin and borrelidin (Fig. 15) treatments in CaOV-3 cells with respect to TARS
protein and transcript levels and TARS PTMs. This would yield information about
whether or not TARS is modified in response to ER stress, and if TARS modification is
required for its involvement in the UPR.

A

B

C

Fig. 15: Structures of MG132, Monensin and Borrelidin. (A-C) Stick structures of
MG132 (A), monensin (B) and borrelidin (C).
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Another PTM of interest is modification by interferon-stimulated gene 15
(ISG15). ISG15 codes for a protein that is added to peptides in response to IFN activation
(Zhang and Zhang 2011). Viral infection typically causes an increase in IFN levels in the
organism. This enables increased ISG15ylation of proteins, which leads to new proteinprotein interactions. These new interactions increase the antiviral response, and have
potential to influence protein turnover (Zhang and Zhang 2011). In various cancer cell
types, TARS is modified by ISG15 following IFN treatment (Giannakopoulos, Luo et al.
2005, Zhao, Denison et al. 2005, Wong, Pung et al. 2006). Of note, WARS is also found
to be ISG15ylated in these cancer cell types following IFN treatment. This furthers the
role of TARS in disease, and proposes possible mechanistic intervention. Going forward,
we could look at the TARS-ISG15 interaction more closely with respect to TARS
localization, TARS protein interactions and UPR induction. We could also investigate
whether TARS ISG15ylation affects the pro-angiogenic function of TARS. Another
protein relevant to this study that gets ISG15ylated is eukaryotic translation initiation
factor-4E2 (eIF4E2) (Okumura, Zou et al. 2007).

5.3 Integration of Eukaryotic Translation, ER Stress and Hypoxia

5.3.1 Hypoxic Translation Machinery
Eukaryotic translation is regulated by various initiation factors that bind to and
facilitate proper mRNA translation. eIF4E is responsible for binding to and directing the
ribosome to the 5’-cap of mRNA. eIF4E is inactivated by 4EBP, which constitutively
binds to eIF4E and inhibits its interaction with mRNA. When 4EBP is phosphorylated it
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dissociates from eIF4E, which enables eIF4E to carry out its translation initiation
function. Phosphorylation of 4EBP is stimulated by the mTOR complex, which is
regulated by upstream signaling cascades (Hsieh and Ruggero 2010). A recent study
found that under hypoxia the mTOR pathway is inhibited in several types of cancer cells,
which inhibits 4EBP phosphorylation (Uniacke, Perera et al. 2014). These carcinoma
cells were found to recruit eIF4E2 to drive protein synthesis under hypoxia, which led to
tumor cell survival and proliferation (Uniacke, Perera et al. 2014). Furthermore, eIF4E2
was found to form a complex with ribosomal binding protein-4 (RBM4) and hypoxiainducible factor-2α (Hif-2α) under hypoxia, which binds the 5’-cap of mRNA and
enables recruitment to polysomes (Uniacke, Holterman et al. 2012). Given the universal
nature of a hypoxic microenvironment in tumor cells, we hypothesize that TARS is
interacting with the eIF4E2/RBM4/Hif-2α complex when cancer cells are hypoxic.

5.3.2 Does TARS Interact with Hypoxic Translation Machinery in Cancer Cells?
We tested this hypothesis in CaOV-3 cells by exposing cells to increasing time
points of hypoxia, and immunoprecipitating (IP) TARS from total cell lysates to detect
whether eIF4E2, RBM4 and Hif-2α interact with TARS under hypoxia. CaOV-3 cells
were exposed to 0, 4 or 16 h of hypoxia, and cells were immediately lysed once taken out
of hypoxia. TARS was pulled down using magnetic Dynabeads® annealed to an antiTARS antibody, and samples of total cell lysate (Fig. 16A), supernatant following pull
down (Fig. 16B) and pelleted protein (Fig. 16C) were resolved by Western blot.
We were able to successfully pull down TARS as seen by comparison of the 16h
vs. 16h no antibody control TARS blot of the pellet (Fig. 16C). However, these results do
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not clearly show an interaction between TARS and eIF4E2, RBM4 and Hif-2α that is
dependent on hypoxia. In the pelleted protein Western blot (Fig. 16C), the highest levels
of eIF4E2 are seen in the no antibody control, and RBM4 and Hif-2α levels do not
correlate with TARS levels at different time points of hypoxia. Supernatant protein levels
(Fig. 16B) also do not decrease in accordance with TARS pull down of eIF4E2, RBM4 or
Hif-2α. Therefore, we cannot confirm at this time that TARS interacts with hypoxic
translation machinery in cancer cells in a hypoxic-dependent manner.
We were able to show TARS does potentially interact with elements of the
hypoxic translation machinery. Pelleted protein blots confirm that TARS, eIF4E2, RBM4
and Hif-2α are present in samples following IP (Fig. 16C). The levels of these proteins in
the pelleted samples are inconsistent with our hypothesis, however we do show presence
of these four proteins across samples. One point of concern is that the highest levels of
eIF4E2 protein in the pelleted samples (Fig. 16C) are observed in the no antibody control
where we expected the lowest levels of eIF4E2. Therefore, our hypothesis should not be
abandoned entirely, but instead we plan to alter our experimental parameters to observe
this interaction.
In this IP, TARS was pulled down and TARS and hypoxic translation machinery
proteins were blotted back for. Future experiments include a pull down with eIF4E2 to
confirm its interaction with translational machinery. This method was not performed
initially because the necessary eIF4E2 antibody was not available. It is also possible that
the lack of interaction was because we did not leave the CaOV-3 cells in hypoxia for long
enough. In the original study that discovered this hypoxia-induced translational
functionality of eIF4E2, carcinoma cells were in hypoxia for up to 48 h (Uniacke, Perera
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et al. 2014). We also plan to retest this interaction in other cell lines, cancerous and
noncancerous, and to observe how borrelidin affects TARS interaction with this
machinery under hypoxia. Based on this preliminary result, we will continue to pursue
our hypothesis that TARS interacts with hypoxic translation machinery under hypoxia by
modifying our initial experimental parameters.

Figure 16: TARS interacts with members of the hypoxic translation machinery
complex independent of hypoxia. (A-C) Immunoprecipitation of TARS from total cell
lysates of CaOV-3 cells treated with increasing time in hypoxia. Samples were resolved
by Western blot and antibodies against TARS, eIF4E2 (31 kD), RBM4 (40 kD) and Hif2α (118 kD) were used. Representative blots of total cell lysate (A), supernatant
following pull down (B) and protein that was pelleted out in the IP (C) are shown.
* indicates no TARS antibody was bound to the magnetic beads (no antibody control). In
theory, this lane should not pull down any TARS or TARS-interacting proteins from
solution.
Of note, one study found that in breast cancer cells, eIF4E is the dominant capbinding initiation factor under both hypoxia and normoxia, and following Hif-1α
stimulation (Yi, Papadopoulos et al. 2013). The researchers also found that inhibiting the
eIF4E complex under hypoxia decreases VEGF protein levels in a dose-dependent
manner and has no effect on VEGF mRNA levels (Yi, Papadopoulos et al. 2013).
Although this contradicts the Uniacke, Perera et al., 2014 paper, it highlights the
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possibility of tissue-specific mechanisms with respect to translational control under
hypoxia.

5.3.3 Comparison of Monensin and Borrelidin Effects on TARS
TARS protein’s possible interaction with eIF4E2 has potential to be linked with
stimulation of angiogenesis and promotion of tumor cell survival and proliferation. We
speculate that upregulation of TARS protein in the hypoxic tumor microenvironment may
be responsible for facilitating translation of pro-angiogenic proteins, such as VEGF.
There does exist evidence supporting the role of synthetases as mediators of VEGF
translation. Stimulation of human myeloid cells with IFN causes phosphorylation of
EPRS at serine residues leading to the formation of the GAIT complex and subsequent
binding of eIF4G, which inhibits formation of the pre-initiation complex (Jia, Yao et al.
2013, Yao and Fox 2013). In addition to its association with the GAIT complex, a
truncated domain of EPRS counters translational repression by the GAIT complex
creating a “translational trickle” of GAIT target proteins, including VEGF (Yao, Potdar et
al. 2012, Yao, Eswarappa et al. 2015). Unpublished data from our lab confidently
suggests that TARS and EPRS interact in HEK293 cells, suggesting TARS involvement
in regulating translation initiation. If TARS protein is found to directly interact with
eIF4E2 under hypoxic conditions, the next question would be whether or not this
contributes to its pro-angiogenic function.
Extracellular TARS has a well-defined role in angiogenesis while the proangiogenic role of intracellular TARS remains undefined. Previous studies in our lab
found that borrelidin treatment of endothelial cells increases ATF4, TARS and VEGF
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transcript levels, indicating ER stress activation and pro-angiogenic function resulting
from ARS inhibition. This effect was amplified under hypoxic conditions. Similarly,
monensin treatment of CaOV-3 cells caused a dose-dependent increase in TARS, AARS
and VEGF transcript levels (Fig. 12) and a dose-dependent increase in p-eIF2α protein
levels (Fig. 11F), which suggests a simultaneous increase in synthetase expression,
promotion of a pro-angiogenic environment and ER stress induction. Given that the direct
mechanism of action for monensin on ARSs and transcription/translation machinery is
unknown, we can conclude that ER stress stimulation of the PERK pathway by monensin
seems to be coupled with increased VEGF transcript levels and an increase in certain
ARS family member’s expression. Borrelidin and monensin treatments both suggest that
the synthetase transcript increase is not TARS-specific in CaOV-3 cells. This is likely a
survival mechanism that cells use to compensate for ER stress by increasing synthetase
transcript levels, but not necessarily increasing their translation. In contrast, TARS
protein levels in CaOV-3 cells increase in response to monensin (Figs. 7B and 11C) and
decrease in response to borrelidin (Fig. 13C). Theses results were not seen with LARS or
AARS protein levels. This suggests that monensin and borrelidin elicit different ER stress
mechanisms, and that TARS protein plays a specific role in the ER stress response. The
increase in TARS protein and VEGF transcript in response to monensin also furthers the
possible angiogenic roles TARS may have intracellularly. A summary of our observed
ER stress effects in CaOV-3 cells and possible integration with hypoxic translation
machinery is depicted below (Fig. 17).
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Figure 17: Summary of effects of monensin and borrelidin on ER stress and
integration with hypoxic translation. The ER stress effects of borrelidin and monensin
treatments on CaOV-3 cells are represented here. *ATF4 transcript increase has only
been observed with borrelidin treatment of endothelial cells. Possible integration between
the ER stress effects and the hypoxia translation mechanism in cancer cells is depicted.
These two processes could theoretically occur in the same cell simultaneously.

5.4 Final Remarks

The ARS family is necessary for protein synthesis, and has gained attention over
the past few decades due to the involvement of various family members in disease.
Extracellular TARS stimulates angiogenesis and cell migration in endothelial cells,
however its mechanism of secretion remains unresolved. TARS is secreted from CaOV-3
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cells in response to an exosome stimulator, monensin, suggesting that exosomal release is
the mechanism for TARS secretion. In addition, monensin stimulates ER stress in CaOV3 cells, which causes an increase in TARS protein and transcript levels as well as an
increase in VEGF transcript levels. TARS protein has potential to be post-translationally
modified, which would affect TARS’ intracellular localization and would enable new
protein-protein interactions for TARS. It is possible ER stress may cause TARS to be
post-translationally modified. TARS may also have increased expression in order to
maintain basal translation rate of specific proteins, such as VEGF, under ER stress or
hypoxia. Comparison of monensin and borrelidin treatments on various cell types has
yielded insightful data about regulation of TARS expression following cell stress.
Although we were unable to confirm TARS secretion by exosomal release from CaOV-3
cells, we gained invaluable information regarding conditions surrounding increased
intracellular TARS expression, which allowed us to predict other non-canonical functions
of TARS.
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CHAPTER 7: APPENDIX
Table A.1: NanoSight particle analysis of exosome-precipitated samples from
CaOV-3 cells.

Mean Particle
Size ± Std.
Error (nm)
Mode Particle
Size ± Std.
Error (nm)
Std. Dev. ±
Std. Error
(nm)
Concentration
± Std. Error
(particles/mL)

ExosomeDepleted
Media
96.4 ± 1.7

Control

10 µM
monensin

50 ng/mL
VEGF

138.5 ± 3.0

135.2 ± 9.2

117.6 ± 6.5

99.6 ± 16.7

98.1 ± 4.7

86.0 ± 7.1

83.7 ± 6.5

24.4 ± 1.7

72.4 ± 5.4

68.8 ± 10.2

52.5 ± 9.1

1.21x108 ±
8.30 x 106

6.07x108 ±
4.27x107

5.95x108 ±
6.08x107

6.74x108 ±
1.49x107

Cell media was collected and exosomes were precipitated out of solution using
ExoQuick-TC™. A sample of exosome-depleted media was precipitated as a negative
control. Pelleted exosomes were resuspended in clean PBS, and run on the NanoSight
instrument. Nanoparticle Tracking Analysis tracked particles between 10-2000 nm in
diameter for 749 frames to yield these results.
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